Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Anticipates High-speed Growth After Merger (China)

This article was originally published in PharmAsia News

Executive Summary

Bayer Schering Pharmaceuticals China expects to maintain growth of over 30 percent in the market, as the merger of the healthcare units of Bayer and Schering nears completion. Liam Condon, managing director of Bayer Healthcare China and chief of Bayer Schering Pharmaceuticals China, reports Bayer Schering saw growth of about 50 percent in 2005 and is targeting a further 30 to 50 percent this year. "Our business scale (this year) will be much larger than last year's for sure," says Condon. U.S. healthcare industry research company IMS Health says that China's pharmaceutical market will grow by 14.4 percent this year. The Chinese pharmaceutical market is shifting focus from antibiotics to treatment for cancers, cardiovascular and cerebrovascular diseases, and diabetes. Bayer Schering also plans to introduce more of its blockbuster medicines to the Chinese market. (Click here for more

You may also be interested in...

Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts